UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15 (d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported) April
19, 2005
ADVENTRX
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
(State or
other jurisdiction of incorporation)
|
001-32157
(Commission
File Number) |
|
84-1318182
(IRS
Employer Identification No.) |
6725
Mesa Ridge Road, Suite 100
San
Diego, California 92121
(Address
of principal executive offices) (Zip Code)
(858)
552-0866
(Company’s
telephone number, including area code)
Item
8.01. Other Events.
On April
19, 2005, the Company announced that it presented CoFactor toxicity and
pharmacodynamics data from its Phase II clinical trial in metastatic colorectal
cancer. In addition, the Company announced that it presented enhanced antitumor
activity and lower systemic toxicity with CoFactor combination therapies in
preclinical models for colorectal and pancreatic cancer.
The press
releases issued by the Company on April 19, 2005 with respect to these matters
are included with this report as exhibits.
Item
9.01. Financial Statements and Exhibits.
| (99) |
©The
exhibit list required by this item is incorporated by reference to the
Exhibit Index filed as part of this report. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ADVENTRX
Pharmaceuticals, Inc. |
|
By: |
/s/
Carrie E. Carlander |
|
Name:
Carrie E. Carlander |
|
Title:
Chief Financial Officer, Vice President, Finance, and
Treasurer
April
19, 2005 |
EXHIBIT
INDEX
|
Exhibit
|
Description
|
|
99.1
|
Press
Release of the Company dated April 19, 2005.
|
|
99.2
|
Press
Release of the Company dated April 19, 2005
|